Ann: Rett Syndrome Patients to Receive NTI164 for 52 Weeks, page-3

Maybe not a duster, but could also be inconclusive - hence the reason to extend the trial to ensure the numbers are interpreted correctly.

All in all not sure if this is a good sign or not - however as you said bad news would have expected to leak via Westmead at this stage you would think, IMO.

Other point is the market doesnt like uncertainty, so unfortunately I reckon they wont like this news - but (like NEU before it) the science is what matters in the end, as opposed to daily SP fluctuations.

Best of luck to holders, and hoping for a good PhII result !!